Inferra AIResearch Tools

Inferra AI / Company / REPL

Replimune Group, Inc.

REPL · Health Care

Last earnings Oct 28, 2026

AI analysis

Q2 2026 · reported Nov 6, 2025

Based on: Earnings release + parent 8-K + 10-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Woburn

Based on: Earnings release + parent 8-K + 10-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

The leading tumor specific cohort in the IGNYTE trial is our registration directed Phase 2 expansion cohort in anti-PD-1 failed cutaneous melanoma.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

The FDA accepted our BLA and granted priority review with a Prescription Drug User Fee Act, or PDUFA, goal date of July 22, 2025.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

In that announcement, we reported that the FDA indicated that it will treat the BLA resubmission as an urgent matter upon receipt and will prioritize its review in recognition of the significant unmet need for patients in the advanced melanoma community.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

Without an accelerated approval of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma from this resubmitted BLA we might not be able to continue the development of RP1 for this indication, if at all, and we may be required to implement a restructuring plan and review our priorities across the RPx portfolio and the company as a whole.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

Due to program prioritization we are currently not pursuing further development of RP3 at this time.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

Risks & headwinds

Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements.

SEC original ↗Replimune Group, Inc. — Earnings release (8-K exhibit)EX-99Nov 6, 2025

Legal proceedings 61 Item 4.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

Such forward-looking statements are subject to various risks and uncertainties.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K.

SEC original ↗Replimune Group, Inc. — 10-K Annual report10-KJun 29, 2026

Documents

Earnings deck slides

0 decks with slide view

Replimune Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

28 documents

Earnings releases

9 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Replimune Group, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.